Post-hoc EMBARK trial analysis: PSA as predictive market for metastasis

[Maxone73]

Ok, we are the NFL of cancer, as I usually say, but this is interesting for all the warriors with no metastasis...

Phase 3 EMBARK trial post-hoc analysis highlights enzalutamide's effectiveness in rapidly achieving and maintaining undetectable PSA levels in patients with high-risk biochemically recurrent prostate cancer.

Patients treated with enzalutamide, alone or combined with leuprolide, had notably better outcomes than those receiving leuprolide alone.

These benefits also correlated with improved metastasis-free survival, emphasizing enzalutamide's clinical potential for aggressive prostate cancer management.

Interestingly: robust PSA control is linked to improved metastasis-free survival independently from the treatment.

prostatewarriors.com/2025/0...